Control of Foxo1 gene expression by co-activator P300 [Metabolism]

December 30th, 2013 by Wondisford, A. R., Xiong, L., Chang, E., Meng, S., Meyers, D. J., Li, M., Cole, P. A., He, L.

FOXO1 is an important downstream mediator of the insulin signaling pathway. In the fed state, elevated insulin phosphorylates FOXO1 via AKT, leading to its nuclear exclusion and degradation. A reduction in nuclear FOXO1 levels then leads to suppression of hepatic glucose production. However, the mechanism leading to expression of Foxo1 gene in the fasted state is less clear. We found that Foxo1 mRNA and FOXO1 protein levels of Foxo1 were increased significantly in the liver of mice after 16h of fasting. Furthermore, Bt-cAMP stimulated the expression of Foxo1 at both mRNA and protein level in hepatocytes. Since cAMP-PKA regulates hepatic glucose production through CREB co-activators, we depleted these co-activators using adenoviral shRNAs. Interestingly, only depletion of co-activator P300 resulted in the decrease of Foxo1 mRNA and FOXO1 protein levels. In addition, inhibition of histone acetyltransferase activity of P300 significantly decreased hepatic Foxo1 mRNA and FOXO1 protein levels in fasted mice, as well as fasting blood glucose levels. By characterization of Foxo1 gene promoter, P300 regulates the Foxo1 gene expression through the binding to the tandem CRE sites in the proximal promoter region of Foxo1 gene.